FIELD: biotechnology.
SUBSTANCE: described is an artificial gene Stbl_RBD_TrM_SC2 used to create a vaccine against SARS-CoV-2 coronavirus, coding an artificial protein-immunogen, which is a bicistronic structure consisting of receptor-binding domain (RBD) sequences of SARS-CoV-2 coronavirus glycoprotein S, heterological signal peptide haemagglutinin (HA) of influenza A virus, transmembrane region, linker, P2A-peptide for splitting polyprotein during translation and glycoprotein G with mutation M(1)>P(1), preventing alternative translation initiation, presented in SEQ ID NO:1 with length of 2463 bp. Described is a recombinant plasmid pStem-rVSV-Stbl_RBD_TrM_SC2, having molecular weight of 8.92⋅106 dalton, size 14417 bp, presented in Fig. 2. Disclosed is a strain of rVSV-Stbl_RBD_TrM_SC2 of recombinant virus of vesicular stomatitis obtained using a recombinant plasmid pStem-rVSV-Stbl_RBD_TrM_SC2, which provides independent synthesis of coronavirus antigen (receptor-binding domain of glycoprotein S of SARS-CoV-2 with transmembrane region) and G protein of vesicular stomatitis virus, used to create a vaccine against SARS-CoV-2 coronavirus and deposited in the State collection of viral infection causative agents, rickettsioses of State Research Center of Virology and Biotechnology VECTOR of Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, No. V-983.
EFFECT: technical result is improved folding of the transmembrane immunogen, higher stability of the target transgene and immunogenic / antigenic properties of the declared recombinant virus.
3 cl, 4 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ARTIFICIAL GENE CODING A BICISTRONIC STRUCTURE FORMED BY RECEPTOR-BINDING DOMAIN SEQUENCES OF THE GLYCOPROTEIN S OF THE SARS-COV-2 CORONAVIRUS, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733831C1 |
| ARTIFICIAL ECTOS_SC2 GENE ENCODING AN ECTODOMAIN OF THE SARS-COV-2 CORONAVIRUS S GLYCOPROTEIN WITH A C-TERMINAL TRIMERIZATION DOMAIN, A RECOMBINANT PLASMID PSTEM-RVSV-ECTOS_SC2, WHICH PROVIDES EXPRESSION OF THE ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-ECTOS_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733834C1 |
| ARTIFICIAL GENETIC CONSTRUCT FOR THE HETEROLOGOUS EXPRESSION OF THE S-PROTEIN RECEPTOR-BINDING DOMAIN IN A FUSED POLYPEPTIDE CHAIN WITH A NUCLEOCAPSID PROTEIN | 2022 |
|
RU2801597C1 |
| MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
| ARTIFICIAL GENE N1NEW, ENCODING NUCLEOCAPSID PROTEIN OF CORONAVIRUS SARS-CoV-2, AND RECOMBINANT PLASMID PET-28A-N1NEW, PROVIDING EXPRESSION OF THE ARTIFICIAL GENE | 2021 |
|
RU2762962C1 |
| RECOMBINANT PLASMID PVBL-RBDDELTA PROVIDING SYNTHESIS AND SECRETION OF THE RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF THE SARS-COV-2 CORONAVIRUS LINE B.1.617.2 IN MAMMALIAN CELLS | 2021 |
|
RU2772904C1 |
| RECOMBINANT PLASMID PVBL-RBDOMIK PROVIDING SYNTHESIS AND SECRETION OF THE RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF THE SARS-COV-2 CORONAVIRUS LINE B.1.1.529 IN MAMMALIAN CELLS. | 2021 |
|
RU2772905C1 |
| INTEGRATIVE PLASMID VECTOR pVEAL3-RBDdel, PROVIDING SYNTHESIS AND SECRETION OF RECOMBINANT PROTEIN OF RECEPTOR-BINDING DOMAIN RBDdelta OF CORONAVIRUS SARS-CoV-2 IN MAMMALIAN CELLS, RECOMBINANT CELL LINE STRAIN CHO-K1-RBDdelta AND RECOMBINANT PROTEIN RBDdelta SARS-CoV-2 PRODUCED BY CELL LINE STRAIN | 2023 |
|
RU2816175C1 |
| Immunobiological agent and method of use thereof for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 (embodiments) | 2020 |
|
RU2720614C1 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
